Dermik Laboratories Inc

Ortho-McNeil-Janssen Pharmaceuticals offers a range of health care products for the treatment of several infectious diseases, as well as pain management. The company s sister concern Ortho-McNeil, which serves primary care hospitals and other care facilities. Ortho-McNeil s products are available under the DURAGESIC, LEVAQUIN, FLOXIN, NIZORAL and PROPULSID brads. The company provides injections, shampoos, caplets, tablets and capsules. Ortho-McNeil offers the ACIPHEX product, which is used of the treatment of heartburn and other symptoms associated with acid reflux disease. The company additionally provides the DORIBAX product for patients with gram negative infections. Ortho-McNeil undertakes several research and development activities.

The Medicines Company develops products that improve acute hospital care and meets the demands of some of the world's most advanced medical practitioners. The company markets Angiomax for injection, an anticoagulant approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company utilizes its range of clinical and commercial skills to develop products acquired from leading life science innovators. In addition to the approved Angiomax product, The Medicines Company is developing clevidipine, a short-acting calcium channel blocker. The Medicines Company is also conducting significant clinical research to study potential additional indications for Angiomax use. In December of 2003, the Company acquired cangrelor, an anticoagulant that prevents platelet clotting factors from activating, which the company believes has potential uses in coronary angioplasty and cardiac surgery. The Medicines Company has offices in Parsippany, N.J., Waltham, Mass., and Abingdon, United Kingdom.